#### Values presented in table
* Strategy and Case 
* expected utility (u)
* assumed true hazard rate (HR)
* threshold value for the decision rule to go to phase III (HR<sub>go</sub>)
* total number of events for phase II (d<sub>2</sub>)
* total expected number of events for one phase III (d<sub>3</sub>)
* total expected number of events in the program (d)
* total sample size for phase II (n<sub>2</sub>)
* total expected sample size for one phase III (n<sub>3</sub>)
* total expected sample size in the program (n)
* probability to go to phase III (p<sub>go</sub>)
* probability of a successful program (sProg)
* probability of a successful program with small effect (sProg1)
* probability of a successful program with medium effect (sProg2)
* probability of a successful program with large effect (sProg3)
* costs for phase II (K2)
* costs for phase III (K3)

and further input parameters.


#### References

FDA guidance for industry: providing clinical evidence of effectiveness for human drug and biological products, 1998. Available at: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072008.pdf (accessed last 21.05.2019).

Fisher, L. D. (1999). One large, well-designed, multicenter study as an alternative to the usual FDA paradigm. <i>Drug Information Journal</i> 33, 265-271.

Preussler, S., Kieser, M., and Kirchner, M. (2019). Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed. <i>Biometrical Journal</i>, 61(2), 357-378.

#### Further Software

The software drugdevelopR (available via: https://web.imbi.uni-heidelberg.de/drugdevelopR/) includes further Apps and an R package for optimal phase II/III drug development planning. The Code, detailed user manuals and application examples can be found on Github (https://github.com/Sterniii3/drugdevelopR).  

#### Note

If the server is busy, you may need to double click the "Go"-button in order to see the updated plot.


#### Maintainer
Stella Preussler, Institute of Medical Biometry and Informatics, University of Heidelberg, email: Preussler@imbi.uni-heidelberg.de.

Beta version 0.4
